SCHEMBL515603

SCHEMBL515603

O=Cc1ccc(C(=O)O)nc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HTM Q9NXG6 14/20 0.65
P4HA1 P13674 1/20 0.55
MIF P14174 1/20 0.55
KDM4E B2RXH2 4/20 0.53
ALDH1A1 P00352 3/20 0.53
L3MBTL1 Q9Y468 4/20 0.47
KMT2A Q03164 2/20 0.47
HIF1A Q16665 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
LMNA P02545 2/20 0.47
MEN1 O00255 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAPT P10636 1/20 0.47
PKM P14618 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
NFKB1 P19838 1/20 0.47
THPO P40225 1/20 0.47
BLM P54132 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2559107 0.85 P4HTM (0.53) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL2645451 0.82 KMT2A (0.50) P4HTMKDM4EALDH1A1L3MBTL1KMT2A
SCHEMBL22046801 0.82 P4HTM (0.44) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL363525 0.82 P4HTM (0.62) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL29953629 0.82 KMT2A (0.50) P4HTMKDM4EALDH1A1L3MBTL1KMT2A
SCHEMBL18573317 0.80 P4HTM (0.71) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL21911853 0.79 P4HTM (0.42) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL25567675 0.79 HDAC1 (0.47) P4HTMKDM4EALDH1A1
SCHEMBL24025440 0.77 P4HTM (0.41) P4HTMP4HA1MIFKDM4EALDH1A1
SCHEMBL9000504 0.77 P4HTM (0.67) P4HTMP4HA1MIFKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119633753-A Activated carbon-based adsorbent for heavy metal ions and preparation method thereof 广东省农业科学院农业资源与环境研究所 2025-03-18 CN claimed
CN-119633753-A Activated carbon-based adsorbent for heavy metal ions and preparation method thereof 广东省农业科学院农业资源与环境研究所 2025-03-18 CN disclosed
US-20240374595-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-11-14 US disclosed
US-12083118-B2 Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same ARBUTUS BIOPHARMA CORPORATION (CA) 2024-09-10 US disclosed
CN-112566905-B Substituted phenylpropenyl pyridine derivatives, preparation method and medical application thereof 上海海雁医药科技有限公司 2024-07-30 CN disclosed
WO-2023141648-A1 2-FLUOROETHYL PROCARBAZINE COMPOUNDS YALE UNIVERSITY (US) 2023-07-27 WO disclosed
US-20230143425-A1 IMPROVEMENTS RELATED TO SORBENT MEDIA GENESIS SYSTEMS LLC 2023-05-11 US disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
EP-3967687-A1 SUBSTITUTED PHENYLPROPENYLPYRIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Shanghai Haiyan Pharmaceutical Technology Co., Ltd (CN) 2022-03-16 EP disclosed
US-20210052585-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2021-02-25 US disclosed
US-20100197667-A1 BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS THERAVANCE, INC. (US) 2010-08-05 US disclosed
US-7728144-B2 Biphenyl compounds useful as muscarinic receptor antagonists THERAVANCE, INC (US) 2010-06-01 US disclosed
EP-1893577-A1 BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS Theravance, Inc. (US) 2008-03-05 EP disclosed
US-20070265310-A1 Biphenyl compounds useful as muscarinic receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC 2007-11-15 US disclosed
US-7265133-B2 Biphenyl compounds useful as muscarinic receptor antagonists THERAVANCE, INC. (US) 2007-09-04 US disclosed
WO-2006138218-A1 BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS THERAVANCE, INC. (US) 2006-12-28 WO disclosed
US-20060281740-A1 Biphenyl compounds useful as muscarinic receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC 2006-12-14 US disclosed
EP-1723108-A1 BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS Theravance, Inc. (US) 2006-11-22 EP disclosed
WO-2005087733-A1 BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS THERAVANCE, INC. (US) 2005-09-22 WO disclosed
US-20050203138-A1 Biphenylylaminocarbonyl-amino- or -oxypiperidine derivatives, e.g., biphenyl-2-ylcarbamic acid 1-[2-((4-[(4-hydroxybenzylamino)methyl]benzoyl)methylamino)ethyl]piperidin-4-yl ester; treating bronchodilation, asthma and chronic obstructive pulmonary disease (COPD) THERAVANCE, INC. 2005-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12083118-B2 Substituted 1,1′-biphenyl compounds, analogues thereof, and methods using same HAVCR2, HMBS, BCL3 P4HTM 796/4885P4HA1 720/4885MIF 2428/4885
US-20100197667-A1 BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS CHRM2, CHRM3, CHRM5 P4HTM 2341/4885P4HA1 4431/4885MIF 3040/4885
US-20070265310-A1 Biphenyl compounds useful as muscarinic receptor antagonists CHRM1, CHRM2, CHRM3 P4HTM 1822/4885P4HA1 2923/4885MIF 3985/4885
US-20240374595-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME HAVCR2, HMBS, CDV3 P4HTM 806/4885P4HA1 706/4885MIF 2409/4885
US-20050203138-A1 Biphenylylaminocarbonyl-amino- or -oxypiperidine derivatives, e.g., biphenyl-2-ylcarbamic acid 1-[2-((4-[(4-hydroxybenzylamino)methyl]benzoyl)methylamino)ethyl]piperidin-4-yl ester; treating bronchodilation, asthma and chronic obstructive pulmonary disease (COPD) CHRM1, CHRM2, CHRM3 P4HTM 361/4885P4HA1 479/4885MIF 4296/4885
US-20210052585-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME HAVCR2, HMBS, CDV3 P4HTM 737/4885P4HA1 664/4885MIF 2504/4885
US-20060281740-A1 Biphenyl compounds useful as muscarinic receptor antagonists CHRM2, CHRM3, CHRM5 P4HTM 2341/4885P4HA1 4431/4885MIF 3040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.